RENUVION® RECEIVES FDA CLEARANCE FOR SPECIFIC USE AFTER LIPOSUCTION
/PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX), the manufacturer of the proprietary helium plasma and radiofrequency technology marketed and sold as...
Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® for Coagulation of Subcutaneous Soft Tissues Following Liposuction for Aesthetic Body Contouring
Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced it has received...
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023
Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that financial...